{"filing":{"accession_number":"0001193125-26-332742","cik":"0001609809","ticker":"MCRB","company_name":"Seres Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-07-31","primary_document":"d133274d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/d133274d8k.htm"},"events":[{"id":23886,"run_id":21603,"accession_number":"0001193125-26-332742","anchor_item_number":"1.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"summary":"Seres Therapeutics entered into a lease termination and amendment agreement on July 31, 2026, to early-terminate approximately 31% of its Cambridge facility, reducing annual facilities costs and restoration obligations. The transaction involves material financial consideration including a $2.2M increase to letter of credit, a $3.85M deferred payment, and a $0.5M equity issuance (103,520 shares).","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24241,"accession_number":"0001193125-26-332742","item_number":"1.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"Seres Therapeutics entered into a lease termination and amendment agreement on July 31, 2026, to early-terminate approximately 31% of its Cambridge facility (21,295 of 68,636 sq ft), reducing annual facilities costs and restoration obligations. The transaction involves material financial consideration: a $2.2M increase to letter of credit, a $3.85M deferred payment, and a $0.5M equity issuance (103,520 shares). While this is a material definitive agreement under Item 1.01, it is primarily a real estate restructuring and cost-reduction measure rather than a traditional M\u0026A activity, debt issuance, or dilutive equity offering. The equity component is incidental to the lease termination rather than the primary event. This is best classified as a material financial event that does not fit the specific categories of debt_issuance or dilutive_issuance, making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:18.975410+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24242,"accession_number":"0001193125-26-332742","item_number":"1.02","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"Item 1.02 discloses termination of a material definitive agreement, specifically a lease amendment and termination agreement referenced in Item 1.01. While the exact nature and financial impact are not detailed in this excerpt, the termination of a material lease obligation represents a material financial event affecting the registrant's obligations and cash position. The materiality threshold for Item 1.02 filings typically indicates investor-relevant changes to contractual obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:18.975410+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24241,"accession_number":"0001193125-26-332742","item_number":"1.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"Seres Therapeutics entered into a lease termination and amendment agreement on July 31, 2026, to early-terminate approximately 31% of its Cambridge facility (21,295 of 68,636 sq ft), reducing annual facilities costs and restoration obligations. The transaction involves material financial consideration: a $2.2M increase to letter of credit, a $3.85M deferred payment, and a $0.5M equity issuance (103,520 shares). While this is a material definitive agreement under Item 1.01, it is primarily a real estate restructuring and cost-reduction measure rather than a traditional M\u0026A activity, debt issuance, or dilutive equity offering. The equity component is incidental to the lease termination rather than the primary event. This is best classified as a material financial event that does not fit the specific categories of debt_issuance or dilutive_issuance, making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:18.975410+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-08-04"},{"id":24242,"accession_number":"0001193125-26-332742","item_number":"1.02","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"Item 1.02 discloses termination of a material definitive agreement, specifically a lease amendment and termination agreement referenced in Item 1.01. While the exact nature and financial impact are not detailed in this excerpt, the termination of a material lease obligation represents a material financial event affecting the registrant's obligations and cash position. The materiality threshold for Item 1.02 filings typically indicates investor-relevant changes to contractual obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:18.975410+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-08-04"}]}